Lo A, Holmes K, Kamlapurkar S, et al. Multiomic characterization of oncogenic signaling mediated by wild-type and mutant RIT1. Sci Signal. 2021;14(711):eabc4520. doi:10.1126/scisignal.abc4520
Luo T, Masson K, Jaffe JD, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012;109(8):2860-5. doi:10.1073/pnas.1120589109
Shen H, Shih J, Hollern DP, et al. Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep. 2018;23(11):3392-3406. doi:10.1016/j.celrep.2018.05.039
Way GP, Sanchez-Vega F, La K, et al. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Rep. 2018;23(1):172-180.e3. doi:10.1016/j.celrep.2018.03.046
Shao W, Mishina YM, Feng Y, et al. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF. Cancer Res. 2018;78(6):1537-1548. doi:10.1158/0008-5472.CAN-17-2033
Chen H, Cade BE, Gleason KJ, et al. Multiethnic Meta-Analysis Identifies RAI1 as a Possible Obstructive Sleep Apnea-related Quantitative Trait Locus in Men. Am J Respir Cell Mol Biol. 2018;58(3):391-401. doi:10.1165/rcmb.2017-0237OC
Shaw AT, Winslow MM, Magendantz M, et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A. 2011;108(21):8773-8. doi:10.1073/pnas.1105941108
Zhang G, Feenstra B, Bacelis J, et al. Genetic Associations with Gestational Duration and Spontaneous Preterm Birth. N Engl J Med. 2017;377(12):1156-1167. doi:10.1056/NEJMoa1612665
Tothova Z, Ebert BL. Doubling Down on Mutant RAS Can MEK or Break Leukemia. Cell. 2017;168(5):749-750. doi:10.1016/j.cell.2017.02.013
Holsinger LJ, Spencer DM, Austin DJ, Schreiber SL, Crabtree GR. Signal transduction in T lymphocytes using a conditional allele of Sos. Proc Natl Acad Sci U S A. 1995;92(21):9810-4.